Physician profile
Usman Khan
NPI 1316269392
$4,941.60
in general payments reported to CMS, 2019-2025
23 companies · $516 in 2025
The $516 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $322 · 2020: $167 · 2021: $599 · 2022: $2,547 · 2023: $517 · 2024: $274 · 2025: $516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,169 · Education: $137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,169.47 |
| Education | $137.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $2,362.08 | 2020-2023 | Penumbra System |
| Boston Scientific Corporation | $804.08 | 2020-2024 | Ranger, Accolade Sr, Angiojet Ultra 5000a |
| Abiomed | $398.34 | 2022-2025 | |
| Actelion Pharmaceuticals US, INC. | $348.04 | 2023-2024 | Uptravi, Opsumit |
| Medtronic Vascular, INC. | $206.44 | 2019 | |
| Medical Device Business Services, INC. | $137.01 | 2025 | Stratafix |
| Astrazeneca Pharmaceuticals LP | $127.96 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $71.64 | 2021-2022 | |
| Pfizer INC. | $69.74 | 2019-2023 | |
| Abbott Laboratories | $43.75 | 2023 | Diamondback Peripheral |
| Ethicon US, LLC | $39.81 | 2025 | Stratafix, Vistaseal |
| Amarin Pharma, INC. | $38.56 | 2020 | |
| Novartis Pharmaceuticals Corporation | $38.35 | 2022-2023 | |
| Cardiovascular Systems INC. | $30.01 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals, LTD. | $24.04 | 2021 | |
| Bardy Diagnostics, INC. | $21.53 | 2021 | |
| Inari Medical, INC. | $19.69 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Terumo Medical Corporation | $17.07 | 2025 | Angio-Seal, Glidewire, Optitorque |
| E.R. Squibb & Sons, L.L.C. | $15.33 | 2022 | |
| Alnylam Pharmaceuticals INC. | $13.75 | 2024 | Amvuttra |
| Celgene Corporation | $13.65 | 2021 | |
| Chiesi USA, INC. | $13.43 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Usman Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.